Ogurtsova K., da Rocha Fernandes J.D., Huang Y. et al. IDF Diabetes Atlas: Global estimates

for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.

DOI: 10.1016/j.diabres.2017.03.024.

Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной

медицинской помощи больным сахарным диабетом. Под ред. Дедова И.И.,

Шестаковой М.В., Майорова А.Ю. 9-й выпуск. Сахарный диабет. 2019;22(1S1):1–144.

[Dedov I.I., Shestakova M.V., Mayorov A. Yu. et al. Algorithms for specialized medical care for

patients with diabetes mellitus. Ed. by I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov. 9th edition.

Diabetes mellitus. 2019;22(1S1):1–144 (in Russ.)].

Makrilakis K. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes

Mellitus: When to Select, What to Expect. Int J Environ Res Public Health. 2019;16(15):2720.

DOI: 10.3390/ijerph16152720.4.

Drucker D.J. Deciphering metabolic messages from the gut drives therapeutic innovation:

the 2014 Banting Lecture. Diabetes. 2015;64(2):317–326. DOI: 10.2337/db14-1514.5.

Deacon C.F. Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the

Treatment of Type 2 Diabetes. Front Endocrinol (Lausanne). 2019;10:80. DOI:

3389/fendo.2019.00080.

Mulvihill E.E., Drucker D.J. Pharmacology, physiology, and mechanisms of action of

dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992–1019. DOI: 10.1210/er.2014-

Mulvihill E.E. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the

incretin axis and regulation of postprandial glucose and lipid metabolism. Peptides.

;100:158–164. DOI: 10.1016/j.peptides.2017.11.023.

Davies M.J., D’Alessio D.A., Fradkin J. et al. Management of Hyperglycemia in Type 2

Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the

European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–

DOI: 10.2337/dci18-0033.

Eriksson J.W., Bodegard J., Nathanson D. et al. Sulphonylurea compared to DPP-4 inhibitors

in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular

events, and all-cause mortality. Diabetes Res Clin Pract. 2016;117:39–47. DOI:

1016/j.diabres.2016.04.055.

Deacon C.F. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized

controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):34–46. DOI: 10.1111/dom.13135.

Roussel R., Duran-Garcнa S., Zhang Y. et al. Double-blind, randomized clinical trial

comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4

inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes:

The CompoSIT-I Study. Diabetes Obes Metab. 2019;21(4):781–790. DOI: 10.1111/dom.13574.

Chen K., Kang D., Yu M. et al. Direct head-to-head comparison of glycaemic durability of

dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes

mellitus: A meta-analysis of long-term randomized controlled trials. Diabetes Obes Metab.

;20(4):1029–1033. DOI: 10.1111/dom.13147.

Liatis S., Dafoulas G.E., Kani C. et al. The prevalence and treatment patterns of diabetes in

the Greek population based on real-world data from the nation-wide prescription database.

Diabetes Res Clin Pract. 2016;118:162–167. DOI: 10.1016/j.diabres.2016.06.018.

Schott G., Martinez Y.V., Ediriweera de Silva R.E. et al. Effectiveness and safety of

dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a

systematic review and development of recommendations to reduce inappropriate prescribing.

BMC Geriatr. 2017;17(Suppl 1):226. DOI: 10.1186/s12877-017-0571-8.

Мисникова И.В. Влияние ингибиторов дипептидилпептидазы-4 на риск развития

сердечно-сосудистых заболеваний у пациентов с сахарным диабетом 2-го типа. РМЖ.

;1:51–52. [Misnikova I.V. The effect of dipeptidyl peptidase-4 inhibitors on the risk of

developing cardiovascular diseases in patients with type 2 diabetes mellitus. RMJ. 2016;1:51–

(in Russ.)].

Демидова Т.Ю., Кожевников А.А. Доверяй и VERIFY: роль комбинированной терапии

метформином и ингибиторами дипептидилпептидазы-4 в дебюте сахарного диабета 2

типа. РМЖ. Медицинское обозрение. 2020;6:334–339. [Demidova T.Yu.,

Kozhevnikov A.A. Trust and VERIFY: the role of combined treatment with metformin and

dipeptidyl peptidase-4 inhibitors in new-onset diabetes type 2. Russian Medical Inquiry.

;4(6):334–339 (in Russ.)]. DOI: 10.32364/2587-6821-2020-4-6-334-339.

Sesti G., Avogaro A., Belcastro S. et al. Ten years of experience with DPP-4 inhibitors for

the treatment of type 2 diabetes mellitus. Acta Diabetol. 2019;56(6):605–617. DOI:

1007/s00592-018-1271-3.

Sesti G., Antonelli Incalzi R., Bonora E. et al. Management of diabetes in older adults. Nutr

Metab Cardiovasc Dis. 2018;28(3):206–218. DOI: 10.1016/j.numecd.2017.11.007.

Boccardi V., Mecocci P. DPP-4 inhibitors: meeting the needs of the very old population.

Acta Diabetol. 2019;56(7):819. DOI: 10.1007/s00592-019-01329-2.

Bekiari E., Rizava C., Athanasiadou E. et al. Systematic review and meta-analysis of

vildagliptin for treatment of type 2 diabetes. Endocrine. 2016;52(3):458–480. DOI:

1007/s12020-015-0841-1.

Scirica B.M., Braunwald E., Raz I. et al. SAVOR-TIMI 53 Steering Committee and

Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-

TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588. DOI:

1161/CIRCULATIONAHA.114.010389.

Zannad F., Cannon C.P., Cushman W.C.B. et al. EXAMINE Investigators. Heart failure and

mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in

EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076.

DOI: 10.1016/S0140-6736 (14) 62225-X.

Green J.B., Bethel M.A., Armstrong P.W. et al. TECOS Study Group. Effect of Sitagliptin on

Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232–242. DOI:

1056/NEJMoa1501352.

Rosenstock J., Perkovic V., Johansen O.E. et al. CARMELINA Investigators. Effect of

Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and

High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA.

;321(1):69–79. DOI: 10.1001/jama.2018.18269.

McGuire D.K., Alexander J.H., Johansen O.E. et al. CARMELINA Investigators. Linagliptin

Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at

High Cardiovascular and Renal Risk in CARMELINA. Circulation. 2019;139(3):351–361. DOI:

1161/CIRCULATIONAHA.118.038352.

Kaneko M., Narukawa M. Assessment of the Risk of Hospitalization for Heart Failure With

Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type

Diabetes, Using an Alternative Measure to the Hazard Ratio. Ann Pharmacother.

;51(7):570–576. DOI: 10.1177/1060028017698496.

Liu D., Jin B., Chen W., Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular

outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-

analysis. BMC Pharmacol Toxicol. 2019;20(1):15. DOI: 10.1186/s40360-019-0293-y.

Oliveira B.C., Marques V.B., Brun B.F. et al. Dipeptidyl peptidase-4 inhibition prevents

vascular dysfunction induced by β-adrenergic hyperactivity. Biomed Pharmacother.

;113:108733. DOI: 10.1016/j.biopha.2019.108733.

Noma K., Kihara Y., Higashi Y. Limited Extent of Pleiotropic Effects Mediated by Dipeptidyl

Peptidase-4 Inhibitors in Patients With Diabetes Mellitus. Circ J. 2018;82(8):1996–1998. DOI:

1253/circj.CJ-18-0694.

Knapen L.M., van Dalem J., Keulemans Y.C. et al. Use of incretin agents and risk of

pancreatic cancer: a population-based cohort study. Diabetes Obes Metab. 2016;18(3):258–

DOI: 10.1111/dom.12605.

Knapen L.M., de Jong R.G., Driessen J.H. et al. Use of incretin agents and risk of acute and

chronic pancreatitis: A population-based cohort study. Diabetes Obes Metab. 2017;19(3):401–

DOI: 10.1111/dom.12833.

Egan A.G., Blind E., Dunder K. et al. Pancreatic safety of incretin-based drugs — FDA and

EMA assessment. N Engl J Med. 2014;370(9):794–797. DOI: 10.1056/NEJMp1314078.

Gamble J.M., Donnan J.R., Chibrikov E. et al. Comparative Safety of Dipeptidyl Peptidase-4

Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute

Outcomes. Sci Rep. 2018;8(1):15142. DOI: 10.1038/s41598-018-33483-y.

Abrahami D., Douros A., Yin H. et al. Dipeptidyl peptidase-4 inhibitors and incidence of

inflammatory bowel disease among patients with type 2 diabetes: population based cohort

study. BMJ. 2018;360: k872. DOI: 10.1136/bmj.k872.

Бабенко А.Ю., Мосикян А.А., Макаренко И.Е. и др. Анализ эффективности и

безопасности эвоглиптина по сравнению с ситаглиптином при добавлении к

монотерапии метформином в русско-корейской популяции. Результаты исследования

ЭВОКОМБИ. Сахарный диабет. 2018;21(4):241–254. [Babenko A. Yu., Mosikyan A.A.,

Makarenko I.E. et al. Analysis of the efficacy and safety of evogliptin compared to sitagliptin

when added to metformin monotherapy in the Russian-Korean population. EVOCOMBI

research results. Diabetes mellitus. 2018;21(4):241–254 (in Russ.)].

Мосикян А.А., Бабенко А.Ю., Севастьянова Ю.А. и др. Предикторы эффективности

терапии Эвоглиптином в российско-корейской популяции пациентов с сахарным

диабетом 2 типа. Сахарный диабет. 2018;21(5):333–343. [Mosikyan A.A., Babenko A.Yu.,

Sevastyanova Yu.A. et al. Predictors of the effectiveness of Evogliptin therapy in the Russian-

Korean population of patients with type 2 diabetes mellitus. Diabetes mellitus.

;21(5):333–343 (in Russ.)].

Kim G., Lim S., Kwon H.S. et al. Efficacy and safety of evogliptin treatment in patients with

type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-

label extension (the EVERGREEN study). Diabetes Obes Metab. 2020;22(9):1527–1536. DOI:

1111/dom.14061.